| P50 | author | Richard G Gorlick | Q56427012 |
| | Richard B Lock | Q61292565 |
| | Malcolm A Smith | Q62764622 |
| | C P Reynolds | Q67015887 |
| | Min H Kang | Q73476305 |
| | John M. Maris | Q90622519 |
| | Stephen T Keir | Q96125453 |
| | Peter J. Houghton | Q112045947 |
| | E Anders Kolb | Q114424051 |
| | Hernan Carol | Q114424052 |
| P2093 | author name string | Christopher L Morton | |
| | Amy Watkins | |
| P2860 | cites work | Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation | Q40383692 |
| | The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. | Q40399567 |
| | Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies | Q40533053 |
| | Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia | Q40719234 |
| | Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma | Q44739121 |
| | The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation | Q44930505 |
| | The pediatric preclinical testing program: description of models and early testing results. | Q48387109 |
| | Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia. | Q53796172 |
| | Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. | Q55471778 |
| | Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents | Q55486128 |
| | Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor | Q60021739 |
| | Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants | Q80421985 |
| | Hotspot mutations of BRAF gene are not associated with pediatric solid neoplasms | Q81016585 |
| | Structural and functional alterations of FLT3 in acute myeloid leukemia | Q24338964 |
| | Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia | Q27851423 |
| | Sorafenib in advanced hepatocellular carcinoma | Q27861075 |
| | Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation | Q28242368 |
| | Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF | Q28251989 |
| | Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 |
| | Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling | Q28296761 |
| | Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas | Q28299301 |
| | BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 |
| | Antitumor activity of sorafenib in FLT3-driven leukemic cells | Q33268279 |
| | FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. | Q33680292 |
| | Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. | Q33754603 |
| | Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia | Q33913329 |
| | Molecular characterization of the pediatric preclinical testing panel | Q34406965 |
| | BAY 43-9006 inhibition of oncogenic RET mutants | Q34565246 |
| | Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement | Q35570953 |
| | Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006) | Q35607396 |
| | Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling | Q36288956 |
| | BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas | Q36532504 |
| | Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. | Q36610990 |
| | Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis | Q36612290 |
| | Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas | Q36992993 |
| | Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials | Q37008436 |
| | Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer | Q37177949 |
| | Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia | Q37198180 |
| | A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations | Q39789949 |
| | Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program | Q40009993 |
| | Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program | Q40141410 |
| | Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. | Q40147444 |
| | The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors | Q40182316 |
| | Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. | Q40192837 |
| | Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models | Q40198053 |
| P433 | issue | 6 | |
| P304 | page(s) | 1126-1133 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | Pediatric Blood & Cancer | Q15754342 |
| P1476 | title | Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program | |
| P478 | volume | 55 | |